Break Up Big Medicine

Summary#

The Break Up Big Medicine Act would bar single companies from owning both certain medical providers (like physician practices, pharmacies, hospitals, and management services organizations) and either (a) an insurance company together with a pharmacy benefit manager (PBM), or (b) a prescription drug or medical device wholesaler. The bill requires firms that violate the rule to divest (sell or otherwise separate) one side of the business within one year and gives the Federal Trade Commission (FTC), the Justice Department (Antitrust Division), states, and private parties tools to enforce the rule. The stated goal is to reduce conflicts of interest from vertical integration and restore competition in health care markets.

Important changes

• It becomes illegal for a person to both (A) own or control a provider or management services organization (MSO) and (B) own or control an insurance company and a PBM at the same time. Violators must divest one side within one year.
• It also becomes illegal for a person to both own or control a provider or MSO and a prescription drug or medical device wholesaler; violators must divest within one year.
• The FTC and the Justice Department share enforcement authority. State attorneys general and private individuals can sue for damages (including treble damages) and equitable relief.
• Penalties for missing divestment milestones include monthly transfers of 10% of the person’s profits into escrow. If divestiture never happens, those funds can be deposited into an FTC fund for community health use.
• The FTC must make rules to carry out the law, and both FTC and DOJ must review divestitures and can block future actions that would recreate the conflicts.

What it means for you#

• Insurers, pharmacy benefit managers (PBMs), and wholesalers

  • Companies that currently own or control both a provider/MSO and an insurer-plus-PBM, or a provider/MSO and a wholesaler, would need to choose and divest one side of the business within one year.
  • They would face FTC/DOJ review of divestitures and potential trusteeship if they fail to divest.

• Health care providers and MSOs (physician practices, pharmacies, ambulatory surgery centers, hospitals, post-acute care, home health, etc.)

  • Providers employed by or owned by an insurer, PBM, or wholesaler could be sold or separated from their current parent company within a year.
  • This could change employer, management, contracting, or billing arrangements; the bill does not prescribe how those transitions must be handled.

• Patients and consumers

  • The bill aims to reduce incentives for parent companies to steer patients to affiliated providers or drugs. This could affect what networks cover and where patients are referred.
  • It is unclear how quickly any change would reach patients or how care continuity would be preserved during divestitures.

• State attorneys general and private plaintiffs

  • States and private individuals can bring civil suits seeking treble (three times) damages, attorney fees, and equitable relief if harmed by violations.

• Federal agencies (FTC and DOJ)

  • Will need to issue guidance and rules, review divestitures, and may bring civil actions to block harmful deals. The bill requires quarterly compliance reports to Congress.

Expenses#

No publicly available information on a fiscal estimate or formal cost analysis was provided in the bill text or the material supplied.

• The bill creates enforcement and reporting duties for the FTC and DOJ that would likely require staff time and administrative resources (rulemaking, guidance, quarterly reports, merger and divestiture reviews).
• Firms that must divest could incur substantial transaction costs from selling businesses or restructuring operations.
• Penalties for failing to meet divestiture milestones include a monthly escrow equal to 10% of the person’s profits; funds may later be distributed by the FTC for community health needs if divestiture does not occur.
• Private litigation (treble damages and attorney fees) could lead to significant costs for businesses found in violation.

Proponents' View#

• The bill appears intended to remove structural conflicts of interest created when a single company controls multiple parts of the health care supply chain.
• A possible argument for the bill is that separating insurers/PBMs/wholesalers from providers will restore competition and reduce incentives to steer patients to affiliated providers or products.
• The bill aims to protect patients, independent providers, pharmacies, and taxpayers by preventing practices that could raise costs or distort care choices.
• It gives enforcement agencies and state attorneys general clearer authority and tools to force divestitures and block future deals that might recreate conflicts.

Opponents' View#

• One concern is the short divestiture timeline (one year), which may be difficult to meet for large, complicated companies and could disrupt operations or patient care during transitions.
• The bill does not detail how continuity of care, existing contracts, or employee transitions should be handled during divestitures; this may raise practical and legal challenges.
• The broad definitions (for example, of “provider,” “MSO,” and “wholesaler”) could sweep in many kinds of businesses and create uncertainty about what must be sold.
• Requiring separation may eliminate some efficiencies or coordination that integrated systems claim help with care management and cost control; the bill does not quantify such trade-offs.
• Allowing private suits with treble damages could increase litigation risk and defensive costs for firms, possibly affecting prices or availability of services.